Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Oxford Bio Advances Boehringer Oncology Candidate | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Oxford Bio Advances Boehringer Oncology Candidate

Receives another milestone payment from Boehringer Ingelheim for progressing a second oncology drug candidate (BI 765049) into the clinic.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, has received another milestone payment from Boehringer Ingelheim (BI) for progressing a second oncology drug candidate (BI 765049) into the clinic.
 
In this Phase 1 clinical trial, BI 765049, will be administered to patients with advanced solid tumors including colorectal cancer, gastric carcinoma, pancreatic carcinoma, non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinoma.
 
“The advancement of the second oncology drug candidate, developed under our collaboration with BI, into the clinic is a major validation of our proprietary OGAP® drug discovery platform”, said OBT’s Chief Executive Officer, Dr. Christian Rohlff.  “Selecting the right target is fundamental for the successful development of a first-in-class antibody drug product. OBT’s platforms are designed to discover and engineer antibody constructs to novel therapeutic targets – these include bi-specific, Chimeric Antigen Receptor T Cell (CAR-T), Antibody Drug Conjugate (ADC) and Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) therapeutics – to best address difficult-to-treat cancers. We believe that the advancement of the first two BI compounds, directed to an oncology target identified by us, into the clinic, further validates our approach.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics